# A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group

> **NCT00986895** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 32 (actual)

## Conditions studied

- Hepatic Encephalopathy
- Urea Cycle Disorders

## Interventions

- **DRUG:** HPN-100

## Key facts

- **NCT ID:** NCT00986895
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00986895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00986895, "A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00986895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*